PET/CT Imaging in Carriers of TTR Mutations
Starting soon
Conditions studied: ATTR, ATTR Gene Mutation, Cardiomyopathy, Transthyretin Mediated Amyloidosis (ATTR)
In brief
The purpose of this study is to determine if TTR gene carriers have early signs of a type of heart disease called amyloidosis using a new radiotracer dye (iodine-124 evuzamitide, I-124E). Participants will undergo a screening that includes a medical history review and completion of quality-of-life surveys. Once screening is complete, participants will undergo an imaging test called a positron emission tomography (PET) scan combined with computed tomography (PET/CT) to make images of the body. The new radiotracer dye (I-124E, a radioactive contrast) will be used during the PET/CT to make amyloidosis visible in the heart and body.
Key facts
- Study ID
- NCT07591038
- Run by
- University of Texas Southwestern Medical Center
- People needed
- 80
- Starts
- 2026-08-01
- Expected to finish
- 2030-06-30
- Last updated by the study team
- 2026-05-19
Who can join
Age: 30 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- UT Southwestern Medical Center — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.